古塞奇尤單抗

古塞奇尤單抗
单克隆抗体
种类完整抗体
目標介白素-23（英语：interleukin-23）
臨床資料
商品名（英语：Drug nomenclature）Tremfya
AHFS/Drugs.comMonograph
MedlinePlusa617036
核准狀況
懷孕分級
给药途径皮下注射
ATC碼
法律規範狀態
法律規範
识别信息
CAS号1350289-85-8
DrugBank
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6402H9864N1676O1994S42
摩尔质量143,561.59 g·mol−1

古塞奇尤單抗（英語：Guselkumab），商品名特諾雅（英語：Tremfya），用於治疗斑块状银屑病、乾癬性關節炎和溃疡性结肠炎[7] [8][9][10][11]。它是一個皮下注射的单克隆抗体，可结合并阻断介白素-23（英语：interleukin-23）[7]。

常见的副作用包括上呼吸道感染[7]。其他副作用包括可能感染、头痛、关节痛、肝脏问题以及疫苗效益下降[12]。孕期的安全性仍不明確[12]。

古塞奇尤單抗于 2017 年在美国和欧洲取得醫疗使用許可[12] [7]。

參考文獻

[编辑]
  1. ^ Tremfya (Guselkumab) Australian Product Information. Department of Health, Therapeutic Goods Administration. The Australian Government. 
  2. ^ Product information. health-products.canada.ca. 2017-11-27 [2024-03-18]. 
  3. ^ Skin health. 加拿大衛生部. 9 May 2018 [13 April 2024]. 
  4. ^ Tremfya 100 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). (emc). 1 November 2020 [12 June 2021]. 
  5. ^ Tremfya- guselkumab injection. DailyMed. [22 January 2021]. 
  6. ^ European Medicines Agency. 欧洲药品管理局 {EMA). 17 September 2018 [12 June 2021]. 
  7. ^ 7.0 7.1 7.2 7.3 Tremfya. [9 December 2021]. （原始内容存档于22 November 2021）. 
  8. ^ Guselkumab. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (National Institute of Diabetes and Digestive and Kidney Diseases). June 2018. PMID 31643594. 
  9. ^ Guselkumab Injection. MedlinePlus Drug Information. 
  10. ^ Guselkumab. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (National Institute of Diabetes and Digestive and Kidney Diseases). June 2018. PMID 31643594. 
  11. ^ TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease. Johnson & Johnson. 
  12. ^ 12.0 12.1 12.2 Guselkumab Monograph for Professionals. Drugs.com. [9 December 2021]. （原始内容存档于27 September 2021） （英语）.